Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...